You are about to leave this website and will be redirected to our online portal for healthcare professionals. By continuing, you confirm that you are a healthcare professional.
GlaxoSmithKline exercised its option to exclusively license investigational compound GLPG0778 and its corresponding back-up compound GLPG0555, both discovered and developed within GSKs immuno-inflammatory alliance with Galapagos. GSK has all rights to these compounds, and Galapagos is eligible to receive milestones and up to double-digit royalties on global sales. In the course of 2013, GSK initiated Phase 2 studies with GSK2586184 (formerly GLPG0778) in systemic lupus erythematosus, chronic plaque psoriasis, and ulcerative colitis. In February 2014, GSK stopped the lupus study due to a lack of effect and put the ulcerative colitis study on hold. In April 2014, GSK informed Galapagos that GSK2586184 met the primary endpoint in a Phase 2a study in psoriasis. In August 2014, GSK informed Galapagos that they have assessed the overall risk:benefit profile of GSK2586184 and have elected to terminate all indications where GSK 2586184 is administered orally for chronic immuno-inflammatory disease (SLE, psoriasis, ulcerative colitis). Development options for GSK2586184 in other potential indications are presently being explored by GSK.
GSK2586184 is the second selective JAK1 molecule discovered by Galapagos to have been evaluated in Phase 2 studies.
For more information about ongoing clinical trials for GSK2586184, please click here.
